– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – –…
SHANGHAI, March 31, 2026 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform…
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue…
March 28, 2026 15:00 ET | Source: Roivant Sciences The results of the Phase 3 VALOR trial were published in…
SHENZHEN, China, March 27, 2026 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading…
SHANGHAI, March 26, 2026 /PRNewswire/ -- JOY GROUP has announced its financial results for the 2025 fiscal year, achieving annual…
TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company")…
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year…
Continues Above-Market Growth with Expanding MarginsAUBURN HILLS, Mich., March 24, 2026 /PRNewswire/ -- Nexteer Automotive (HK 1316) today reported financial…
Group PerformanceRevenue: US$959.5 million, +61.4% year-on-yearGross profit: US$553.2 million, +103.3% year-on-yearAdjusted net profit: US$230.3 million, +285.0% year-on-yearBusiness Units' PerformanceGenScript Life…